14 15 2 Genome-wide association studies (GWAS) have identified hundreds of genetic variants 16 associated with dyslipidemia. However, about 95% of of these variants are located in genome 17 noncoding regions and cluster in different loci. The disease-causing variant for each locus and 18 underline mechanism remain largely unknown. We systematically analyzed these noncoding 19 variants and found that rs1997243 is the disease-causing variant in locus 7p22, which is 20 strongly associated with hypercholesterolemia. The rs1997243 risk allele is associated with 21 increased expression of GPR146 in human and targeted activation of the rs1997243 site 22 specifically up regulates GPR146 expression in cultured cells. GPR146 is an orphan G-protein 23 coupled receptor that is located on plasma membrane and responses to stimulation of heat-24 inactivated serum. Disrupting gpr146 specifically in the liver decreases the blood cholesterol 25 level and prevents high-fat or high-fat high-cholesterol diets induced hypercholesterolemia in 26 mice. Thus we uncovered a novel G-protein coupled receptor that regulates blood cholesterol 27 level in both human and mouse. Our results also suggest that antagonizing GPR146 function 28 will be an effective strategy to treat hypercholesterolemia. 29
unknown, which prevent the interpretation of the GWAS results and their application in precise 48 medicine. On the other hand, these noncoding regions may harbor novel genes or signaling 49 pathways involved in lipid metabolism and provides a valuable resource for further mechanistic 50 studies. 51
We systematically analyzed these noncoding loci and primarily focused on loci that are not 52 close to any gene known plays a role in lipid metabolism. One such locus 7p22 is strongly associated 53 with increased level of blood cholesterol in multi cohorts [14] [15] [16] (Fig S1a, S2b) . The lead SNP 54 rs1997243 is a common variant and has the highest frequency in European population but is absent 55 in East Asian ( Fig S1b) . It is located in the noncoding region and has a strong linkage disequilibrium 56 non-synonymous variant rs11761941 (GPR146 p. Gly11Glu) in some populations ( Fig S1a, S2a , 57 S2b). Both rs1997243 and rs11761941 are significantly associated with blood cholesterol level (Fig 58 S2b) 15 . However, the GPR146 p. Gly11 is not conserved and has been substituted with Asp, Asn or 59 4 Ala in many other species except Gray wolf ( Fig S2c) . Bioinformatics analysis also predicts that 60 GPR146 p. Gly11Glu is benign and neutral ( Fig S2d) , rendering rs11761941 less likely to be the 61 disease-causing variant. 62
We reasoned that any SNPs that have strong linkage disequilibrium with the lead SNP could be 63 the real disease-causing variant. Since all these variants are located in the noncoding region, the real 64 disease-causing variant is most likely located in the regulatory region, such as regions marked by 65
DNase I hypersensitivity and/or histone modifications marker H3K27ac and H3K4me3 17-21 . We 66 systematically analyzed all SNPs that have strong linkage disequilibrium with the lead SNP 67 rs1997243 in 7p22 locus. There are 125 SNPs were identified, with 28 of them are located in genome 68 active regions ( Fig S3a, S3i , Table S1 ). We then applied luciferase reporter assay to compare the 69 transcriptional activities between the minor allele and the major allele for each of these SNPs. 70
Promoter sequence of APOA1 was used as a positive control for the assay (Fig S3b) . We found that 71 across all SNPs tested, only rs1997243 shows increased promoter activity compared with its 72 reference allele under similar transfection efficiency (Fig 1b, Fig S3c-k) . The rs1997243 does not 73 change enhancer activity in enhancer luciferase reporter assay (Fig 1c, Fig S3l) , which is consistent 74 with enriched promoter specific histone marker H3K4me3 at this position (Fig 1a) 17, 20, 21 . 75
Expression quantitative trait loci (eQTL) analysis showed that the rs1997243 minor allele (G-76 allele) is strongly associated with increased expression of GPR146 in human (Fig 1d) . Targeted 77 activation of rs1997243 site with enzymatic dead Cas9 (dCas9) system and a gRNA specifically to 78 the rs1997243 position increases the expression level of GPR146 significantly, with no detectable 79 impact on other genes in this region (Fig 1e, Fig S2e) . These data suggest that the rs1997243 is the 80 disease-causing variant and may increase blood cholesterol level through up regulating GPR146 81 5 expression. 82 GPR146 is an orphan G-protein coupled receptor that is highly expressed in liver and adipose 83 tissue of both human and mouse ( Fig S4a, Fig 2a) . In the liver, it specifically expresses in 84 hepatocytes (Fig 2b) . By prediction, it contains typical seven transmembrane domains with N 85 terminal facing extracellular compartment ( Fig S4b, c) . When expressed in cells, GPR146 is located 86 in membrane fraction and is located on plasma membrane, which suggests that it may function as a 87 receptor (Fig 2c, d) . GPCRs typically signaling through Gs, Gi/o, Gq/11, G12/13 or Gand 88 regulate cAMP production, intracellular Ca 2+ mobilizations, ERK/MAPK activity or small G protein 89
RhoA activity et al 22 . We found that GPR146 responses to serum filtered by 3 kDa cut-off filter and 90 activates the transcriptional activity of cAMP response element (CRE) (Fig 2e) . Moreover, this 91 response is preserved when the serum was further heat-inactivated by boiling and can be fully 92 blocked by PKA inhibitor H-89 ( Fig 2f) . Taken together, our data suggests that GPR146 is a cell 93 signaling receptor that responses to serum stimulation and activates the PKA signaling pathway. 94
To further study its function in vivo, we generated gpr146 knockout mouse model with Cre-95
LoxP system ( Fig S5a) . Totally we got 6 lines of LoxP positive F1 mice and they were genotyped 96 by genome sequencing (data not shown), southern blot analysis ( Fig S5b) and PCR genotyping ( Fig  97   S5c ). Line 92 was used for all experiments except otherwise indicated. We generated whole body, 98 liver specific and adipose tissue specific gpr146 knockout mice by crossing the LoxP/LoxP mice 99 with Cre recombinase driven by CMV, albumin and adiponectin promoters respectively. Whole 100 body gpr146 -/mice have significantly decreased blood cholesterol level compared with their 101 littermate controls ( Fig S6a, b) . In contrast, the adipose tissue specific gpr146 -/mice have no 102 detectable difference of blood lipids levels compared with their littermate controls ( Fig S6c, d) . The 6 liver specific gpr146 -/-(Li-gpr146 -/-) mice have significantly decreased blood cholesterol level as 104 the whole body gpr146 -/mice and are protected from high-fat high-cholesterol diet induced 105 hypercholesterolemia (Fig 3a-d) , which suggest that gpr146 regulates blood cholesterol level mainly 106 through the liver. Consistent with decreased plasma cholesterol level, both ApoB-100 and ApoB-48 107 protein levels are significantly decreased in the plasma, especially under high-fat high-cholesterol 108 diet feeding (Fig 3e, f) . ApoA1 is also slightly decreased in Li-gpr146 -/mice under high-fat high-109
cholesterol diet feeding (Fig 3e, f) . Moreover, Li-gpr146 -/mice are protected from high-fat diet 110 induced hypercholesterolemia (Fig 4a) . To test whether acutely suppressing gpr146 will decrease 111 blood cholesterol level, we knocked down gpr146 in livers of adult mice through adeno-associated 112 virus mediated shRNA delivering. As shown in Figure 4b , knocking down gpr146 in the liver 113 significantly decreases the blood cholesterol level, which indicates that blocking gpr146 function 114 will be an effective strategy to decrease blood cholesterol in adults. These results were confirmed 115 in Li-gpr146 -/mice derived from an independent F1 line (Fig 4c, d, Fig S5b) . Taken together, our 116 results clearly demonstrate that GPR146 positively regulates blood cholesterol level, which is 117 consistent with increased blood cholesterol level in humans with rs1997243 minor allele. 118
In summary, through bioinformatics analysis and experimental verification we found a 119 noncoding disease-causing variant rs1997243 in locus 7p22. The risk allele of rs1997243 up 120 regulates an orphan G-protein coupled receptor GPR146 that plays an important role in regulating 121 blood cholesterol level. We believe that the increased expression level of GPR146 can at least 122 partially explain the disease-causing effect of rs1997243 in human. 123
In contrast to the causal variants in Mendelian disease, which typically confer large effect, the 124 common variants from GWAS usually have modest effects for each of them. This is especially true 125 7 for GWAS SNPs that are located in genome noncoding regions. However, variants that explain a 126 small proportion of the traits may provide substantial biological or therapeutic insights. The 127 rs1997243 confers a modest effect on total blood cholesterol level with effect size of 0.033 14 . 128
However, combining bioinformatics analysis and functional studies we found that the downstream 129 target gene GPR146 has a large impact on blood cholesterol level. Our data also reveal that GPR146 130 responses to an endogenous ligand in the serum and actives the PKA signaling pathway, which 131 suggest that GPR146 is a functional GPCR and has therapeutic potential. Thus our study provides 132 an example that the common noncoding variant with modest effect may provide important 133 biological or therapeutics insights. The strategy we developed here can be applied to other 134 noncoding loci with unknown mechanisms as well. 135
Our study should be interpreted within the context of its limitations. First, we systematically 136 analyzed all SNPs in 200 Kb window across the locus and found that rs1997243 is the only variant 137 that changes promoter activity of the genome sequence and increases the expression level of 138 GPR146. We cannot exclude the possibility that there exist other variants that extremely far away 139 from the lead SNP and mediate the disease-causing effect together with rs1997243. However, our 140 study provides compelling evidences that rs1997243 is the disease-causing variant and increases 141 GPR146 expression level, which at least contributes to the increased blood cholesterol level in 142 human. Second, our animal models strongly suggest that Gpr146 regulates blood cholesterol level 143 mainly through the liver. However, eQTL analysis showed that the strongest association for GPR146 144 expression level and the rs1997243 risk allele is in human whole blood cells. Thus we cannot 145 exclude the possibility that GPR146 may regulate blood cholesterol level through other tissues 146 together with liver in human. Third, we found that gpr146 knockout mice have decreased blood 147 8 cholesterol level, however the underline mechanism needs further investigation. Our preliminary 148 data (not shown) indicate that the gpr146 knockout mice have normal food intake and fecal 149 cholesterol excretion rate, which suggest that the decreased blood cholesterol could be caused by 150 decreased cholesterol secretion into circulation or increased cholesterol clearance from the 151
circulation. 152
During preparation of this manuscript, Dr. Cowan's group reported the phenotypic 153 characterization of gpr146 knockout mice 23 . They reported that gpr146 knockout mice have 154 decreased level of blood cholesterol, which is consistent with our results. However, our results 155 provide genetic evidence that GPR146 regulates blood cholesterol level not only in mice but also in 156 human. First, although the 7p22 locus is strongly associated with hypercholesterolemia, we are the 157 first to show that the rs1997243 is the disease-causing variant in this locus. Second, we provide 158 multiple evidences that the rs1997243 risk allele specifically up regulates the expression level of 159 GPR146 in this locus. Third, by generating the gpr146 knockout mouse models, we provide strong 160 evidences that Gpr146 positively regulates blood cholesterol level mainly through the liver. 161
Altogether, our results indicate that GPR146 is an important regulator of blood cholesterol level in 162 both human and mouse. Together with the decreased atherosclerosis in gpr146 knockout mice in Dr. 163
Cowan's report 23 , we believe GPR146 will be an attractive drug target for hypercholesterolemia and 164 atherosclerotic cardiovascular diseases. 
Luciferase reporter assay 202
For promoter activity assay, about 2 kb genome sequence covering indicated SNPs were amplified 203 from HepG2 genome using primers listed in Table S2 . The DNA fragments were cloned into 204 upstream of firefly luciferase through Xho1 and Kpn1 in pGL3-basic vector (Promega, E1751). For 205 enhancer activity assay, a TATA mini promoter was first cloned into upstream of firefly luciferase 206 and then DNA fragments were cloned into upstream of TATA box through Xho1 and Kpn1 in pGL3-207 mini promoter vector. Corresponding minor alleles for each SNPs were introduced by recombination 208 with primers listed in Table S2 . The firefly luciferase reporter plasmids and renilla luciferase control 209 11 plasmid (Promega, E2241) were co-transfected into HepG2 cells with Lipoplus (Sagecreation, 210 Q03003) according to the instruction. 24 hours after transfection, luciferase activity was determined 211
using Dual-luciferase reporter assay system (Promega, E1960). Firefly luciferase activity was 212 normalized with renilla luciferase activity and the vector transfected group was set to one. 213
Transfection efficiency for each reporters were measured by real-time PCR using DNA extracted 214 from cells in parallel experiments. Specific primers recognizing firefly luciferase and renilla 215 luciferase are listed in Table S2 . 216
The CRE-luciferase reporter was generated by putting the cAMP regulatory elements (CRE) 217 in front of firefly luciferase in pGL4 basic vector (Promega, E134A). hRenilla luciferase (Promega, 218 E692A) was used as internal control. To increase plasma membrane localization of GPR146, a 39 219 amino acids of bovine rhodopsin was fused to the N terminal of GPR146 as described previously 25 . 220
GPR146 expressing plasmid or vector control plasmid was co-transfected with luciferase reporter 221 plasmids by transient transfection using PEI. Eight hours later, cells were changed with serum free 222 medium containing 0.1% fatty acid free BSA (Sangon Biotech, A602448). About 16 hours later, 223 cells were treated with or without indicated amount of fetal bovine serum (FBS) for 6 hours. 224
Luciferase activity was assayed with Dual-luciferase reporter assay system (Promega, E1960). 225
Filtered FBS was made by passing through a 3 kD cut-off filter with centrifugation (Millipore, 226 UFC9003). Heat-inactivated FBS was made by boiling the 3 kD filtered FBS at 95 o C for 10 minutes. 227
Then the serum was span down and the supernatant was collected for experiments. In some 228 experiments, cells were pre-incubated with 10 M of PKA inhibitor H-89 (Selleck, S1582) for 60 229 minutes before FBS treatment. 
Blood chemistry and lipoprotein profiling 254
Plasma total cholesterol and triglyceride levels were measured by enzymatic kits (Shanghai Kehua 255
Bio-Engineering Co). Plasma lipoprotein particles were size fractionated by Fast Protein Liquid 256 Chromatography (FPLC) using a Superose 6 column (GE Healthcare) and the cholesterol content 257 in each fraction was measured accordingly 26 . 258
Immunoblot analysis 259
Biotinylation and immunoblot was performed as described previously 27 except that the cells and 260 liver tissue were lysated in RIPA buffer (50 mM Tris-HCl, pH=8.0, 150 mM NaCl, 0.1% SDS, 1.5% 261 NP40, 0.5% deoxycholate, 2 mM MgCl2). For cell fractionation experiments, cells were 262 homogenized by passing through #7 needle for 60 times on ice. Nuclear pellet was isolated by low 263 speed centrifugation (750 g) for 20 minutes at 4 o C. The supernatant was transferred for high speed 264
(100,000 g) centrifugation for 60 minutes at 4 o C. Then the supernatant was saved as cytosol fraction 265 and the membrane pellet was re-suspended in SDS lysis buffer (10mM Tris-HCl, pH 6.8, 100mM 266 NaCl, 1% SDS, 1mM EDTA, 1 mM EGTA) and incubated at 37 degree for 30 minutes. Then 267 membrane suspension was span down again at 12,000 g for 5 minutes at room temperature and was 268 saved as membrane fraction. The nuclear pellet was re-suspended in nuclear lysate buffer (20mM 269 HEPES/KOH, pH7.6, 2.5% (v/v) glycerol, 1.5mM MgCl2, 0.42M NaCl, 1mM EDTA, 1mM EGTA) 270 and rotates at 4 degree for 1 hour. Then the suspension was span down at 14,000 g for 20 minutes 271 at 4 o C and the supernatant was saved as nuclear fraction. Cytosol, membrane and nuclear fractions 272 were added with sample buffer and incubated at 37 degree for 30 minutes and then subjected to 273 immunoblot analysis. To detect apolipoproteins, the fresh blood was collected into EDTA coated 274 tubules containing aprotinin (Sigma, A1153-25MG). Then plasma was isolated at 4 degree and was 275 14 subjected to immunoblots analysis. 276
The following antibodies were used in this study: anti-Flag antibody (Medical & Biological 277 Laboratories, PM020); anti-calnexin antibody (Proteintech, 10427-2-AP); anti-Actin antibody 278 (Proteintech, 20536-1-AP), anti-Lamin B1 antibody (Proteintech, 20536-1-AP), anti-GPR146 279 antibody (CUSABIO,CSB-PA006863), anti-ATP1A1 antibody (Abclonal, A0643), anti-ApoB 280 antibody 26 and anti-ApoA1 antibody (Proteintech, 14427-1-AP). 281
Real-Time PCR analysis 282
Total RNA was extracted from cells or mouse tissues using TRI Reagent (Sigma-Aldrich, T9424). 283
The quality and concentration of RNA were measured with NanoDrop ONE c (Thermo Scientific). 284 cDNA was synthesized from 2 μg of total RNA using a cDNA Reverse Transcription Kit (Thermo 285 Scientific, M1682). The cDNA was quantified by Real-Time PCR using SYBR Green master mix 286 (YEASEN Biotech Co, 11201ES08). Reactions were running in technical duplicate on CFX96 or 287 CFX384 wells plates. Relative quantification was completed using the ΔΔCT method. Gene 288 expression was normalized to housekeeping gene Gapdh, 36B4 or Cyclophilin. 289
Primary hepatocytes and non-hepatocytes 290
Mouse liver was first ligated and a piece of liver was sliced and frozen in liquid N2 as whole liver 291 sample. The left over liver was perfused with wash buffer followed by collagenases 1 digestion 292 buffer exactly the same as described 27 . Then the liver was transferred to a 60 mm dish in cold 293 digestion buffer and the particulate material was filtered through a 70 m filter. The pass through 294 was span down at 40 g*10 minutes for three times at 4 o C. The pellets from each spin were pooled 295 together and are the primary hepatocytes. The supernatant was span down again at 500 g for 10 296 minutes. The pellet was collected as non-hepatocytes. Total RNA was extracted and 2 g of RNA 297 15 was subjected to reverse transcription as described above followed by real-time PCR analysis. 298
Adeno-associated virus packaging and purification 299
Adeno-associated virus was produced in 293T cells by co-transfecting the shRNA expression AAV 300 shuttle plasmid together with Delta F6 helper plasmid, Rev Cap 2/9 plasmids using PEI. 60 hours 301 after transfection, cells were harvested and freeze-thaw in lipid nitrogen for five times. Then 302
Benzonase Nuclease (Sigma, E1014) was added and incubated at 37 degree for 45 minutes. After 303 centrifugation at 4000 rpm for 30 minutes, the supernatant was collected and added on top of the 304 iodixanol gradient (15%, 25%, 40%, 58%). Then the sample was centrifuged at 48000 rpm in a 305
Beckman type 70Ti rotor for 130 minutes at 18 degree. The fraction in the 40% iodixanol was 306 collected and dialyzed with 1×PBS extensively. The titer of the virus was determined by qRT-PCR. 307
To knock down gpr146 in the liver, each mouse was infused with 1X10 11 virus particles through tail 308 vein and samples were collected at one and two weeks after injection. The shRNA sequence against 309 gpr146 was listed in Table S2 . 310
Data analysis 311
All data are expressed as mean ± SEM and p values were calculated using Student's test in GraphPad 312 unless otherwise indicated. 
